Safety and Clinical Performance of the Next-Generation SAFESYNC Transcatheter Heart Valve in Patients With Severe Aortic Stenosis (SAFESYNC NG)
Evaluation of the Safety and Clinical Performance of the Next-Generation SAFESYNC Balloon-Expandable Transcatheter Heart Valve in Patients With Severe Aortic Stenosis: A Prospective, Multicenter, Single-Arm Pivotal Study
This pivotal, prospective, multicenter (Brazil, Chile and Argentina), single-arm study will evaluate the safety and clinical performance of the Inovare® Safesync Next-Generation bioprosthetic heart valve, implanted by transfemoral transcatheter aortic valve implantation (TAVI) with the B-Delivery System, in patients aged 70 years or older with severe aortic stenosis and an indication for TAVI, regardless of surgical risk. The study will enroll 210 participants.
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Tipo de estudio
Tipo de estudio
Inscripción (Estimado)
Inscripción
Fase
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
Estudio Contacto
- Nombre: Clinical Research Department - Braile Biomédica
- Número de teléfono: +5517 21367000
- Correo electrónico: pesquisa@braile.com.br
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
Severe aortic valve stenosis diagnosed according to criteria established in current guidelines; Age ≥70 years, regardless of surgical risk; Indication for transcatheter aortic valve implantation (TAVI); Willing to participate and to sign the written informed consent form.
Exclusion Criteria:
Any condition considered a contraindication to implantation of a bioprosthetic heart valve (e.g., patient with an indication for a mechanical heart valve);
Known hypersensitivity or contraindication to any of the following that cannot be adequately managed with premedication:
- Aspirin, clopidogrel, or heparin (heparin-induced thrombocytopenia [HIT] or heparin-induced thrombocytopenia with thrombosis [HITTS]);
- Nitinol (titanium or nickel);
- Contrast media; Blood dyscrasias: leukopenia (white blood cell count <1,000/mm³), thrombocytopenia (platelet count <100,000 cells/mm³), history of coagulopathy, or hypercoagulable states; Active infection, including endocarditis; Cardiogenic shock manifested by low cardiac output, vasopressor dependence, or need for mechanical hemodynamic support; Recent stroke or transient ischemic attack (within 6 months); History of gastrointestinal bleeding or other bleeding that precludes anticoagulant or antiplatelet therapy; Estimated life expectancy of less than 5 years; Other medical, social, or psychological conditions that, in the investigator's opinion, prevent the patient from providing consent or adequately complying with the protocol; Pre-existing prosthetic heart valve in the aortic position (biological or mechanical); Concomitant severe mitral or tricuspid valve disease; Hypertrophic obstructive cardiomyopathy; Percutaneous coronary intervention performed within 72 hours prior to the study procedure; Femoral artery diameter <5.5 mm (for Safesync 20 to 24 mm), <6.0 mm (for Safesync 26 and 28 mm), or <6.5 mm (for Safesync 30 mm); High risk of annular rupture or significant residual paravalvular leak due to severe calcification of the aortic valve or left ventricular outflow tract; High risk of coronary obstruction (coronary ostial height <10 mm with narrow sinuses of Valsalva [SOV], defined as a mean SOV diameter <3 mm larger than the bioprosthesis size), as determined by computed tomography angiography; Left ventricular dysfunction with left ventricular ejection fraction (LVEF) ≤30%; Severe chronic kidney disease, defined as glomerular filtration rate <30 mL/min/1.73 m².
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Número de brazos
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Experimental: INOVARE® SAFESYNC Next-Generation TAVI
|
Participants will undergo TAVI via transfemoral access using the INOVARE® SAFESYNC Next-Generation Bioprosthetic Heart Valve and the B-Delivery System. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Device Success According to VARC-3 Criteria
Periodo de tiempo: 30 days after the procedure
|
Technical success; Absence of mortality; Absence of surgery or intervention related to the device or to major vascular, access-related, or cardiac structural complications; Intended valve performance, defined as mean transvalvular gradient <20 mmHg, peak velocity <3 m/s, Doppler velocity index ≥0.25, and less than moderate aortic regurgitation. |
30 days after the procedure
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Percentage of Participants Achieving Technical Success According to VARC-3 Criteria
Periodo de tiempo: During the procedure
|
Defined as freedom from mortality; successful vascular access, delivery of the device, and retrieval of the delivery system; correct positioning of a single prosthetic heart valve in the intended anatomical location; and freedom from surgery or intervention related to the device or to a major vascular, access-related, or cardiac structural complication. Results will be reported as the number and percentage of participants achieving technical success. |
During the procedure
|
|
Incidence and Severity of Paravalvular Leak
Periodo de tiempo: 30 days, 6 months, 12 months, and annually through 5 years
|
Paravalvular leak will be assessed by transthoracic echocardiography and classified according to severity. The number and percentage of participants with paravalvular leak in each severity category will be reported. |
30 days, 6 months, 12 months, and annually through 5 years
|
|
Mean Transvalvular Aortic Pressure Gradient Assessed
Periodo de tiempo: 30 days, 6 months, 12 months, and annually through 5 years
|
Mean transvalvular aortic pressure gradient will be assessed by transthoracic echocardiography and reported in mmHg. |
30 days, 6 months, 12 months, and annually through 5 years
|
|
Distribution of Participants by New York Heart Association Functional Class
Periodo de tiempo: 30 days, 6 months, 12 months, and annually through 5 years
|
Functional status will be assessed using the New York Heart Association (NYHA) Functional Classification. The classification ranges from Class I to Class IV, where Class I represents no limitation of physical activity and Class IV represents inability to perform physical activity without symptoms and/or symptoms at rest. Higher NYHA classes indicate worse functional status. Results will be reported as the number and percentage of participants in each NYHA functional class. |
30 days, 6 months, 12 months, and annually through 5 years
|
|
Incidence of New Permanent Pacemaker Implantation
Periodo de tiempo: 30 days, 6 months, 12 months, and annually through 5 years
|
New permanent pacemaker implantation following the index transcatheter aortic valve implantation procedure will be assessed. Results will be reported as the number and percentage of participants who undergo new permanent pacemaker implantation. |
30 days, 6 months, 12 months, and annually through 5 years
|
|
Incidence of All-Cause Mortality
Periodo de tiempo: 30 days, 6 months, 12 months, and annually through 5 years
|
All-cause mortality will be assessed throughout follow-up. Results will be reported as the number and percentage of participants who die from any cause. |
30 days, 6 months, 12 months, and annually through 5 years
|
|
Incidence of Stroke
Periodo de tiempo: 30 days, 6 months, 12 months, and annually through 5 years
|
Stroke events will be assessed based on clinical neurological evaluation and classified according to Valve Academic Research Consortium 3 (VARC-3) definitions. Results will be reported as the number and percentage of participants experiencing stroke. |
30 days, 6 months, 12 months, and annually through 5 years
|
|
Incidence of Bioprosthetic Valve-Related Reintervention
Periodo de tiempo: 30 days, 6 months, 12 months, and annually through 5 years
|
Bioprosthetic valve-related reintervention will be defined as any surgical or transcatheter intervention performed to treat dysfunction or failure of the implanted study valve. Results will be reported as the number and percentage of participants undergoing valve-related reintervention. |
30 days, 6 months, 12 months, and annually through 5 years
|
|
Incidence of Bioprosthetic Valve Dysfunction According to VARC-3 Definitions
Periodo de tiempo: 30 days, 6 months, 12 months, and annually through 5 years
|
Bioprosthetic valve dysfunction will be assessed according to Valve Academic Research Consortium 3 (VARC-3) definitions. Bioprosthetic valve dysfunction includes structural valve deterioration, non-structural valve dysfunction, valve thrombosis, and endocarditis. Results will be reported as the number and percentage of participants meeting the criteria for bioprosthetic valve dysfunction and according to the corresponding category. |
30 days, 6 months, 12 months, and annually through 5 years
|
|
Incidence of Bioprosthetic Valve Failure According to VARC-3 Definitions
Periodo de tiempo: 30 days, 6 months, 12 months, 24 months, 36 months, 48 months, and 60 months after the index procedure
|
Bioprosthetic valve failure will be assessed according to Valve Academic Research Consortium 3 (VARC-3) definitions. Results will be reported as the number and percentage of participants meeting the criteria for bioprosthetic valve failure. |
30 days, 6 months, 12 months, 24 months, 36 months, 48 months, and 60 months after the index procedure
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Inicio del estudio
Finalización primaria (Estimado)
Finalización primaria
Finalización del estudio (Estimado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
Otros números de identificación del estudio
- SAFESYNC NG
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .